AMEX · Medical - Instruments & Supplies

STXS (STXS) Stock

$1.42 +4.41% AMEX: STXS Healthcare

Valuation

MetricValue
Price$1.42
Market Cap$139.07M
P/E Ratio-7.36
P/B Ratio9.47
P/S Ratio5.80
EPS (TTM)$-0.25
52-Week High$3.59
52-Week Low$1.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-115.79%
ROA-42.31%
ROCE-122.22%
Gross Margin-68.75%
Operating Margin-68.75%
Net Margin-69.50%
Debt/Equity0.27
Current Ratio1.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$35.0M$28.0M$27.0M$27.0M$32.0M
Operating Profit$-13.0M$-19.0M$-22.0M$-25.0M$-22.0M
Net Profit$-11.0M$-18.0M$-21.0M$-24.0M$-22.0M
EPS$-0.16$-0.26$-0.27$-0.30$-0.25
Op Margin-36.8%-66.7%-81.6%-91.9%-68.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$61.0M$53.0M$42.0M$47.0M$52.0M
Total Liabilities$22.0M$21.0M$20.0M$35.0M$34.0M
Cash$39.0M$9.0M$20.0M$12.0M$13.0M
Borrowings$6.0M$6.0M$5.0M$6.0M$5.0M

Latest News

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026 GlobeNewswire · Jul 21, 2026 University of Szeged Pioneers First Robotic Cardiology Program in Hungary GlobeNewswire · Jul 20, 2026 Stereotaxis (STXS) Could Be 56% Undervalued After Shelf Registration Filings Simply Wall St. · Jul 20, 2026 Stereotaxis Files Resale Registration for Up to 108.9 Million Shares MT Newswires · Jul 15, 2026 Can ISRG Defend Its Leadership as Global Competition Intensifies? Zacks · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-8.0M$-9.0M$-8.0M$-14.0M
Investing Cash Flow$-3.0M$-24.0M$19.0M$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-4.0M$-30.0M$11.0M$-8.0M$1.0M
Free Cash Flow$-4.0M$-11.0M$-10.0M$-9.0M$-14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-8.58%
Quick Ratio1.10
Interest Coverage—
Return 1Y-29.52%
Return 3Y7.38%
Return 5Y-82.42%

Ownership

Insiders Held15.29%
Institutions Held44.00%
Institutions Float Held51.94%
Institutional HolderSharesReport Date
DAFNA Capital Management, LLC13,680,5542026-03-31
Lagoda Investment Management, L.P.4,350,4002026-03-31
Blackrock Inc.3,956,2432026-03-31
Vanguard Capital Management LLC2,998,0442026-03-31
Arbiter Partners Capital Management LLC2,883,8562026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARCT $6.26 +0.64% -2.93 $177.93M 0.00%
CVRX $4.88 +2.95% -2.98 $129.50M 0.00%
HUMA $0.66 -1.79% -4.19 $110.81M 0.00%
MDXHMDxHealth S.A. $0.42 +1.51% -0.61 $21.38M 0.00%
NEO $13.14 -5.40% -1.96 $342.20M 0.00%

About STXS

STXS is led by CEO David Leo Fischel, employs 139 people, headquartered in US, publicly traded since 2004.

STXS stock trades at $1.42 with a market capitalization of $139.07M. The stock is valued at a price-to-earnings (P/E) ratio of -7.36, price-to-book of 9.47, price-to-sales of 5.80. Over the past 52 weeks the stock has ranged between $1.29 and $3.59, and currently trades 60.4% below its 52-week high.

On profitability, STXS generates a return on equity (ROE) of -115.79%, return on capital employed of -122.22%, an operating margin of -68.75%, a net profit margin of -69.50%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides